Literature DB >> 17500062

Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties.

Brian Christensen1, Christian C Kazanecki, Torben E Petersen, Susan R Rittling, David T Denhardt, Esben S Sørensen.   

Abstract

Osteopontin (OPN) is a highly modified integrin-binding protein found in all body fluids. Expression of OPN is strongly correlated with poor prognosis in many different human cancers, suggesting an important but poorly understood role for this protein in tumorigenesis and metastasis. The protein exists in a number of different isoforms differing in the degree of post-translational modifications that are likely to exhibit different functional properties. This study examines for the first time the post-translational modifications of OPN from transformed cells and the effects of these modifications on cell biology. We have characterized the complete phosphorylation and glycosylation patterns of OPN expressed by murine ras-transformed fibroblasts (FbOPN) and differentiating osteoblasts (ObOPN) by a combination of mass spectrometric analyses and Edman degradation. Mass spectrometric analysis showed masses of 34.9 and 35.9 kDa for FbOPN and ObOPN, respectively. Enzymatic dephosphorylation, sequence, and mass analyses demonstrated that FbOPN contains approximately four phosphate groups distributed over 16 potential phosphorylation sites, whereas ObOPN contains approximately 21 phosphate groups distributed over 27 sites. Five residues are O-glycosylated in both isoforms. These residues are fully modified in FbOPN, whereas one site is partially glycosylated in ObOPN. Although both forms of OPN mediated robust integrin-mediated adhesion of mouse ras-transformed fibroblasts, the less phosphorylated FbOPN mediated binding of MDA-MD-435 human tumor cells almost 6-fold more than the heavy phosphorylated ObOPN. These results strongly support the hypothesis that the degree of phosphorylation of OPN produced by different cell types can regulate its function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17500062     DOI: 10.1074/jbc.M703055200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells.

Authors:  Lauren A Thurgood; Esben S Sørensen; Rosemary L Ryall
Journal:  Urol Res       Date:  2011-09-20

2.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 3.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

4.  The dual role of osteopontin in acetaminophen hepatotoxicity.

Authors:  Chun-yan He; Bei-bei Liang; Xiao-yu Fan; Lei Cao; Rui Chen; Ya-jun Guo; Jian Zhao
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

5.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

6.  Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.

Authors:  Ioanna Giopanou; Ioannis Lilis; Vassilios Papaleonidopoulos; Theodora Agalioti; Nikolaos I Kanellakis; Nikolitsa Spiropoulou; Magda Spella; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

7.  Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1.

Authors:  Hazuki E Miwa; Thomas A Gerken; Oliver Jamison; Lawrence A Tabak
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

8.  Growth of v-src-transformed cells in serum-free medium through the induction of growth factors.

Authors:  Tiziana Deangelis; Andrew Quong; Andrea Morrione; Renato Baserga
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

9.  Progesterone and placentation increase secreted phosphoprotein one (SPP1 or osteopontin) in uterine glands and stroma for histotrophic and hematotrophic support of ovine pregnancy.

Authors:  Kathrin A Dunlap; David W Erikson; Robert C Burghardt; Frank J White; Kristey M Reed; Jennifer L Farmer; Thomas E Spencer; Ronald R Magness; Fuller W Bazer; Kayla J Bayless; Greg A Johnson
Journal:  Biol Reprod       Date:  2008-07-30       Impact factor: 4.285

10.  The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.

Authors:  Donald Courter; Hongbin Cao; Shirley Kwok; Christina Kong; Alice Banh; Peiwen Kuo; Donna M Bouley; Carmen Vice; Odd Terje Brustugun; Nicholas C Denko; Albert C Koong; Amato Giaccia; Quynh-Thu Le
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.